Chinese Herbal Slice Industry In Dire Straits
This article was originally published in PharmAsia News
Executive Summary
The herbal slice industry in China, at 22.3 billion yuan or 15.5 percent of the national Traditional Chinese Medicine market in 2006, is in trouble. China's State FDA has reiterated that manufacturers without GMP authentication, or an estimated 70 percent of firms, are to shut down immediately. According to 2007 year-end statistics, only 288 out of 1,100 registered herbal slice firms have achieved GMP authentication, and 110 have undergone checks but are awaiting certification. While analysts did not expect product shortage or price hikes in the short term, the latest policy will further set back the development and internationalization of the industry, in which 60 percent of GMP authenticated firms are already barely making a profit. (Click here for more)
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.